TG Therapeutics(TGTX)
NEW YORK, NYBiotechnology
Focus: TG Therapeutics is a publicly traded biopharmaceutical company focused on biologics development across oncology, neurology, and immunology. With $234M in FY2025 revenue and a peak-stage marketed product (UKONIQ), the company operates as a mid-cap biotech with commercial traction.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at TG Therapeutics?
AI assessmentMid-cap biotech with validated commercial product and solid pipeline, but minimal hiring and cash burn concerns warrant caution for job seekers expecting growth headcount.
Why Work Here
- Strong revenue inflection: FY2025 revenue jumped 7,700% to $234M, signaling successful product commercialization and real market validation.
- Diverse pipeline with 30 programs across oncology and neurology, including Phase 3 assets in CLL and multiple sclerosis with near-term catalysts.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$234M
Key Products
Stable
Peak8.7yr
Approved monotherapy driving FY2025 revenue inflection; patent protection extends to 2035, providing decade-long exclusivity window.
Help build intelligence for TG Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.